First Trust Advisors LP purchased a new stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 22,491 shares of the biotechnology company’s stock, valued at approximately $2,363,000. First Trust Advisors LP owned approximately 0.05% of bluebird bio at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC grew its holdings in bluebird bio by 0.6% in the first quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock valued at $556,918,000 after purchasing an additional 37,742 shares during the period. Advisors Asset Management Inc. acquired a new stake in shares of bluebird bio in the first quarter worth approximately $858,000. Winfield Associates Inc. boosted its stake in shares of bluebird bio by 6.1% in the second quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock worth $296,000 after acquiring an additional 162 shares during the last quarter. Alliancebernstein L.P. boosted its stake in shares of bluebird bio by 50.1% in the first quarter. Alliancebernstein L.P. now owns 85,860 shares of the biotechnology company’s stock worth $7,805,000 after acquiring an additional 28,640 shares during the last quarter. Finally, Karp Capital Management Corp acquired a new stake in shares of bluebird bio in the first quarter worth approximately $410,000.
A number of equities analysts have weighed in on the company. BTIG Research reissued a “buy” rating and set a $112.00 price objective on shares of bluebird bio in a research note on Thursday, June 1st. Zacks Investment Research downgraded bluebird bio from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub downgraded bluebird bio from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $88.00 price objective on shares of bluebird bio in a report on Friday, August 11th. Finally, Maxim Group upgraded bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $107.86.
In related news, insider Nick Leschly sold 25,000 shares of bluebird bio stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $108.05, for a total transaction of $2,701,250.00. Following the completion of the sale, the insider now owns 360,656 shares of the company’s stock, valued at approximately $38,968,880.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark Vachon sold 6,000 shares of bluebird bio stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $126.82, for a total transaction of $760,920.00. Following the sale, the director now directly owns 8,000 shares of the company’s stock, valued at approximately $1,014,560. The disclosure for this sale can be found here. In the last ninety days, insiders sold 153,248 shares of company stock valued at $17,708,425. 3.90% of the stock is owned by insiders.
Shares of bluebird bio, Inc. (BLUE) opened at 131.60 on Friday. The firm’s 50-day moving average price is $106.30 and its 200-day moving average price is $96.34. The firm’s market cap is $6.00 billion. bluebird bio, Inc. has a one year low of $37.05 and a one year high of $136.85.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm had revenue of $16.70 million during the quarter, compared to analyst estimates of $6.29 million. During the same quarter last year, the business posted ($1.59) earnings per share. The company’s revenue for the quarter was up 977.4% on a year-over-year basis. Equities research analysts expect that bluebird bio, Inc. will post ($6.84) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “First Trust Advisors LP Takes Position in bluebird bio, Inc. (BLUE)” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2017/09/17/22491-shares-in-bluebird-bio-inc-blue-acquired-by-first-trust-advisors-lp.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.